135 related articles for article (PubMed ID: 7105045)
1. Accumulation and release of vinblastine and vincristine by HeLa cells: light microscopic, cinematographic, and biochemical study.
Lengsfeld AM; Dietrich J; Schultze-Maurer B
Cancer Res; 1982 Sep; 42(9):3798-805. PubMed ID: 7105045
[TBL] [Abstract][Full Text] [Related]
2. Vinblastine and vincristine--growth-inhibitory effects correlate with their retention by cultured Nb 2 node lymphoma cells.
Gout PW; Noble RL; Bruchovsky N; Beer CT
Int J Cancer; 1984 Aug; 34(2):245-8. PubMed ID: 6469399
[TBL] [Abstract][Full Text] [Related]
3. Differential activity of vincristine and vinblastine against cultured cells.
Ferguson PJ; Phillips JR; Selner M; Cass CE
Cancer Res; 1984 Aug; 44(8):3307-12. PubMed ID: 6744266
[TBL] [Abstract][Full Text] [Related]
4. Determinants of intrinsic sensitivity to Vinca alkaloids in xenografts of pediatric rhabdomyosarcomas.
Houghton JA; Williams LG; Torrance PM; Houghton PJ
Cancer Res; 1984 Feb; 44(2):582-90. PubMed ID: 6692363
[TBL] [Abstract][Full Text] [Related]
5. Differential cellular retention of vincristine and vinblastine by cultured human promyelocytic leukemia HL-60/Cl cells: the basis of differential toxicity.
Ferguson PJ; Cass CE
Cancer Res; 1985 Nov; 45(11 Pt 1):5480-8. PubMed ID: 3863705
[TBL] [Abstract][Full Text] [Related]
6. Use of snail neurons in developing quantitative ultrastructural parameters for neurotoxic side effects of Vinca antitumor agents.
Müller LJ; Moorer-van Delft CM; Zijl R; Roubos EW
Cancer Res; 1990 Mar; 50(6):1924-8. PubMed ID: 2407348
[TBL] [Abstract][Full Text] [Related]
7. Comparative cell killing and kinetic effects of vincristine or vindesine in mammalian cell lines.
Hill BT; Whelan RD
J Natl Cancer Inst; 1981 Aug; 67(2):437-43. PubMed ID: 6943380
[TBL] [Abstract][Full Text] [Related]
8. Cellular pharmacokinetics of vinblastine and other vinca alkaloids in MO4 cells.
Van Belle SJ; De Smet MC; De Mey JE; Storme GA
Anticancer Res; 1991; 11(1):465-71. PubMed ID: 2018383
[TBL] [Abstract][Full Text] [Related]
9. Effects of vincristine on cell survival, cell cycle progression, and mitotic accumulation in asynchronously growing Sarcoma 180 cells.
Mujagic H; Chen SS; Geist R; Occhipinti SJ; Conger BM; Smith CA; Schuette WH; Shackney SE
Cancer Res; 1983 Aug; 43(8):3591-7. PubMed ID: 6861131
[TBL] [Abstract][Full Text] [Related]
10. Factors governing the modulation of vinca-alkaloid resistance in doxorubicin-resistant cells by the calmodulin inhibitor trifluoperazine.
Ganapathi R; Grabowski D; Schmidt H
Biochem Pharmacol; 1986 Feb; 35(4):673-8. PubMed ID: 3947398
[TBL] [Abstract][Full Text] [Related]
11. Energy-dependent reduced drug binding as a mechanism of Vinca alkaloid resistance in human leukemic lymphoblasts.
Beck WT; Cirtain MC; Lefko JL
Mol Pharmacol; 1983 Nov; 24(3):485-92. PubMed ID: 6579344
[TBL] [Abstract][Full Text] [Related]
12. Structural determinants of phenoxazine type compounds required to modulate the accumulation of vinblastine and vincristine in multidrug-resistant cell lines.
Thimmaiah KN; Horton JK; Qian XD; Beck WT; Houghton JA; Houghton PJ
Cancer Commun; 1990; 2(7):249-59. PubMed ID: 2378785
[TBL] [Abstract][Full Text] [Related]
13. Interphase action of vinblastine and vincristine: differences in their lethal action through the mitotic cycle of cultured mammalian cells.
Madoc-Jones H; Mauro F
J Cell Physiol; 1968 Dec; 72(3):185-96. PubMed ID: 5724569
[No Abstract] [Full Text] [Related]
14. Comparative effects of vindesine, vinblastine, and vincristine on mitotic arrest and hormonal response of L1210 leukemia cells.
Howard SM; Theologides A; Sheppard JR
Cancer Res; 1980 Aug; 40(8 Pt 1):2695-700. PubMed ID: 6248211
[TBL] [Abstract][Full Text] [Related]
15. Cross-resistance of cultured murine leukemia vincristine-resistant P388 cells to vinblastine, vindesine, and bis (N-ethylidene vindesine) disulfide, disulfate.
Wilkoff LJ; Dulmadge EA
J Natl Cancer Inst; 1982 Jun; 68(6):1023-6. PubMed ID: 6953266
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of release of interleukin-2 by vincristine and vinblastine.
Ahmed K; Abdul Hamied TA; Turk JL
Immunopharmacol Immunotoxicol; 1987; 9(4):391-407. PubMed ID: 3501797
[TBL] [Abstract][Full Text] [Related]
17. NMR and mass spectrometric characterization of vinblastine, vincristine and some new related impurities - part I.
Dubrovay Z; Háda V; Béni Z; Szántay C
J Pharm Biomed Anal; 2013 Oct; 84():293-308. PubMed ID: 22985529
[TBL] [Abstract][Full Text] [Related]
18. The action of two Vinca alkaloids on B16 melanoma in vitro.
Donoso JA; Himes RH
Cancer Biochem Biophys; 1984 Jun; 7(2):133-45. PubMed ID: 6467174
[TBL] [Abstract][Full Text] [Related]
19. Continued expression of vinca alkaloid resistance by CCRF-CEM cells after treatment with tunicamycin or pronase.
Beck WT; Cirtain MC
Cancer Res; 1982 Jan; 42(1):184-9. PubMed ID: 7198507
[TBL] [Abstract][Full Text] [Related]
20. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil.
Tsuruo T; Iida H; Tsukagoshi S; Sakurai Y
Cancer Res; 1981 May; 41(5):1967-72. PubMed ID: 7214365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
